Shionogi (United States)

Recent papers from Shionogi (United States)

1. Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paperNPP—Digital Psychiatry and Neuroscience · 2026
2. In vitro activity of cefiderocol against highly resistant Gram-negative pathogens collected in the SENTRY Surveillance Program between 2020 and 2024Journal of Global Antimicrobial Resistance · 2026
3. Current Impact of COVID-19 in Long-Term Care Facilities in the United States: A Systematic Literature ReviewThe Senior Care Pharmacist · 2026
4. Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household ContactsNew England Journal of Medicine · 2026
5. Ensitrelvir for the treatment of hospitalized adults with COVID-19: an international phase 3 randomized placebo-controlled trialClinical Infectious Diseases · 2026
6. Prospective Study of Treatment with Ensitrelvir for COVID-19 in Patients Undergoing Hemodialysis (PROTECT-HD)Infectious Diseases and Therapy · 2026
7. Wcn26-3993 Ensitrelvir Exposure in Covid-19 Patients on Hemodialysis (Protect-Hd)Kidney International Reports · 2026
8. Antimicrobial snapshot: CefiderocolClinical Microbiology Newsletter · 2026
9. Human erythropoietin mRNA as an impurity from a mRNA-LNP vaccine induces immune-mediated anemia in ratsThe Journal of Toxicological Sciences · 2026
10. Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosaJournal of Antimicrobial Chemotherapy · 2026
11. P-1666. Ensitrelvir (ESV) Population Pharmacokinetics (PK) in Nonhospitalized Adults with COVID-19Open Forum Infectious Diseases · 2026
12. P-1300. Activity of Cefiderocol and Comparator Agents Against Metallo-β-Lactamase Carrying Acinetobacter baumannii-calcoaceticus complex Isolates Collected in the SENTRY Antimicrobial Surveillance ProgramOpen Forum Infectious Diseases · 2026
13. β-lactam-β-lactamase Inhibitor Combinations Show a High Degree of Cross Resistance in Gram-negative Bacteria But Not to Cefiderocol; Results from the SENTRY Antimicrobial Surveillance Program (2020-2024)Open Forum Infectious Diseases · 2026
14. P-1198. Inner Zones of Inhibition in Disk Diffusion Testing of Cefiderocol Best Reflect Activity Against Acinetobacter baumanniiOpen Forum Infectious Diseases · 2026
15. P-1220. Analyzing trends of cefiderocol susceptibility across five years of the SENTRY surveillance programOpen Forum Infectious Diseases · 2026
16. P-1310. Cefiderocol Remains Active against US Clinical Isolates of Stenotrophomonas maltophilia Non-susceptible to Comparator Agents: Results from the SENTRY Antimicrobial Surveillance Program (2020–2024)Open Forum Infectious Diseases · 2026
17. P-1352. Clinical Outcomes of Cefiderocol for Treatment of Bloodstream Infections Caused by Gram-Negative Bacteria: Subgroup Analysis of the PROVE StudyOpen Forum Infectious Diseases · 2026
18. P-1353. Earlier Cefiderocol Use was Associated with Better Outcomes for Challenging Gram-Negative Bacterial Infections: US Results From the Global Observational PROVE StudyOpen Forum Infectious Diseases · 2026
19. P-1606. Clearance of Infectious Virus in COVID-19 Patients Treated with Ensitrelvir Across Vaccination Status, Age, and Risk Subgroups: Exploratory Analyses from the SCORPIO-HR StudyOpen Forum Infectious Diseases · 2026
20. P-1354. Outcomes of Patients Treated With Cefiderocol For Infections Caused by β-Lactam–β-Lactamase Inhibitor Non-Susceptible Bacteria: Subgroup Analysis of the PROVE StudyOpen Forum Infectious Diseases · 2026